Adjuvants

Apr 09, 2020

SciMed Solutions Releases Scalable Adjuvant Discovery Software

Feb 24, 2020

Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older

Jan 13, 2020

Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products

Aug 30, 2019

Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response

Aug 22, 2019

Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines at OPTIONS X Conference

Jul 24, 2019

Vaccine Adjuvants Market Growth Factors & Competitive Analysis Report, 2028 | Key Players: SEPPIC, Brenntag Biosector, SPI Pharma, Novavax, & Aphios: Radiant Insights, Inc.

Oct 08, 2018

The global human and animal vaccine adjuvants market size is expected to reach at USD 1.07 billion by 2025

Oct 03, 2018

Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek

May 10, 2018

Pfenex Reports First Quarter 2018 Results and Provides Business Update

Mar 13, 2018

Seqirus answers the call for better and faster influenza vaccine technologies

Nov 13, 2017

First DNA Vaccine Licensed for Chickens

Oct 13, 2017

GSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization from Health Canada